X

Blood Advances

Blood Advances
Optimal Timing and Criteria of Interim PET in DLBCL: A Comparative Study of 1692 Patients

The aim of this study is to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. 

Blood Advances
05/04/2021
Effect of Lisocabtagene Maraleucel on HRQoL and Symptom Severity in Relapsed/Refractory Large B-Cell Lymphoma

HRQoL and symptom improvements across prespecified EORTC QLQ-C30 scales were clinically meaningful in a notable proportion of patients.

Blood Advances
04/27/2021
Comprehensive CRISPR-Cas9 Screens Identify Genetic Determinants of Drug Responsiveness in Multiple Myeloma

The introduction of new drugs in the past years has substantially improved outcome in multiple myeloma.

Blood Advances
05/05/2021
Lenalidomide Triggers T-cell Effector Functions in vivo in Patients With Follicular Lymphoma

Lenalidomide induces early T-cell activation and reprogramming, and restores long-term immune synapse formation in vivo in FL patients.

Blood Advances
04/20/2021
Preclinical Activity and Determinants of Response of the GPRC5DxCD3 Bispecific Antibody Talquetamab in Multiple Myeloma

Talquetamab, the new GPRC5DxCD3 bispecific antibody, actively kills GPRC5D+ MM cell lines and primary MM cells in vitro.

Blood Advances
04/23/2021
Infection-Related Morbidity and Mortality Among Older Patients With DLBCL Treated With Full- or Attenuated-Dose R-CHOP

Increased risk of infection-related hospital admission is independently associated with IDI >80% in older patients with DLBCL.

Blood Advances
04/23/2021
Efficacy and Safety of Prophylactic High-Dose MTX in High-Risk DLBCL: A Treatment Intent–Based Analysis

In high-risk DLBCL patients, prophylactic HD-MTX does not improve CNS or survival outcomes but is associated with increased toxicities.

Blood Advances
04/21/2021
Prospective KIR Genotype Evaluation of Hematopoietic Cell Donors is Feasible With Potential to Benefit Patients With AML

This study demonstrates that donor KIR typing is feasible, and prioritization of donors with certain KIR3DL1 genotypes may confer a protection from relapse after HCT in patients with AML.

Blood Advances
04/12/2021
Efficacy and Safety of Copanlisib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Enhanced efficacy outcomes can result from prolonged duration of copanlisib therapy in patients with relapsed/refractory MZL.

Blood Advances
02/05/2021
Active Surveillance of Primary Extranodal Marginal Zone Lymphoma of Bronchus-Associated Lymphoid Tissue

This retrospective study shows that BALT lymphoma can often be managed expectantly and not require therapy for many years.

Blood Advances
01/15/2021
Subscribe to Blood Advances

source list reference

#7d60d9
#2694a4
#32a887
#85eb24
#352625
#4d4537
#d2093c
#8e3f1c
#76b6c3
#bfcfc8
#c61417
#67e25b
#efef71
#03cffc
#42fc9a
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
#e7f6e3
#6fc969
#9a8c2c
#a9c507
#2b9ab3
#e61923
#990677
#4a7bab
#89f67c
#49a21d
#2c990a
#d7da81
#575662
#a60538
#49cde9
#c20fce
#d95d39